Maxigen Biotech (TPE:1783) Interest Expense: NT$-0.0 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:1783 Maxigen Biotech Inc TPE:1783
87 GF Score
Price NT$40.80
GF Value NT$61.30
Valuation Significantly Undervalued
View Full Analysis

What is Maxigen Biotech Interest Expense?

Maxigen Biotech TPE:1783 +0.99% 87 Interest Expense is NT$-0.0 Mil as of Dec. 2025. GuruFocus rates TPE:1783 with a GF Score™ of 87/100 and a GF Value™ of NT$61.30 (Significantly Undervalued).

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Maxigen Biotech's interest expense for the three months ended in Dec. 2025 was NT$ -0.0 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-0.0 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Maxigen Biotech's Operating Income for the three months ended in Dec. 2025 was NT$ 89.5 Mil. Maxigen Biotech's Interest Expense for the three months ended in Dec. 2025 was NT$ -0.0 Mil. Maxigen Biotech's Interest Coverage for the quarter that ended in Dec. 2025 was 2,081.86. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Maxigen Biotech  (TPE:1783) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Maxigen Biotech's Interest Expense for the three months ended in Dec. 2025 was NT$-0.0 Mil. Its Operating Income for the three months ended in Dec. 2025 was NT$89.5 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2025 was NT$0.0 Mil.

Maxigen Biotech's Interest Coverage for the quarter that ended in Dec. 2025 is calculated as

Interest Coverage=-1* Operating Income (Q: Dec. 2025 )/Interest Expense (Q: Dec. 2025 )
=-1*89.52/-0.043
=2,081.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Maxigen Biotech Inc has enough cash to cover all of its debt. Its financial situation is stable.

Maxigen Biotech Interest Expense Historical Data

* Premium members only.

The historical data trend for Maxigen Biotech's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Maxigen Biotech Interest Expense Chart

Maxigen Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.20 -0.07 0.00 0.00 -0.04

Maxigen Biotech Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -0.04
TPE:1783
87GF Score
Maxigen Biotech Inc TPE:1783
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Maxigen Biotech Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of NT$-0.0 Mil mean?
Maxigen Biotech (TPE:1783) has a Interest Expense of NT$-0.0 Mil as of Dec. 2025. Interest Expense is the amount a company pays on its long-term debt. View historical data on Maxigen Biotech and its competitors.
Is Maxigen Biotech's Interest Expense too high?
Maxigen Biotech's current Interest Expense is NT$-0.0 Mil. Overall, Maxigen Biotech has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Maxigen Biotech's Interest Expense compare to ISRG and BDX?
Maxigen Biotech's Interest Expense of NT$-0.0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Medical Devices & Instruments company?
A good Interest Expense depends on the Medical Devices & Instruments industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Maxigen Biotech and its competitors. Maxigen Biotech's current Interest Expense is NT$-0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maxigen Biotech stock overvalued right now?
Based on GuruFocus' analysis, Maxigen Biotech (TPE:1783) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$61.30, compared to a current price of NT$40.80 — trading 33.4% below its estimated fair value. The current Interest Expense is NT$-0.0 Mil. Maxigen Biotech's overall GF Score™ is 87/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Maxigen Biotech (TPE:1783), the current Interest Expense is NT$-0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Maxigen Biotech (TPE:1783) Overvalued in 2026?

Based on GuruFocus' analysis, Maxigen Biotech stock appears to be undervalued. The current stock price of NT$40.80 is trading 33.4% below its estimated GF Value™ of NT$61.30. GuruFocus considers Maxigen Biotech to be Significantly Undervalued.

Key valuation signals for TPE:1783:

  • Interest Expense: NT$-0.0 Mil
  • GF Value™: NT$61.30 vs. price of NT$40.80 (33.4% below fair value)
  • GF Score™: 87/100

No single metric tells the full story. See the TPE:1783 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Maxigen Biotech Business Description

Address No.88, Keji 1st Road, Guishan District, Taoyuan City, TWN, 333
Maxigen Biotech Inc is engaged in collagen purification, research and development, production and sales of implantable medical device, and production, manufacturing, wholesale and retail of cosmetics. The group had two reportable segments: the biomedical products segment and consumer products segment. Biomedical products segment is engaged in the manufacturing and sales of collagen and bone materials. The consumer products segment is involved in the manufacturing and sales of beauty care products. Geographically, it operates in Taiwan, America, Europe, Asia, and other countries, with the majority of the revenue deriving from Taiwan.
87GF Score

Get the complete analysis for TPE:1783

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$40.80
Price
NT$61.30
GF Value